Lyra Therapeutics Inc (LYRA) Stock Price, Quote & News

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 393 4600

Website: lyratherapeutics.com

Address:

480 Arsenal Way, Watertown, United States

blakely90 Jan. 29 at 1:13 PM

TAOP stock is the next big squeezer, upcoming robotics acquisition with no dilution and a small 1m micro float. These are the types that can go 500% $PBM $INTW $EOSU $LYRA $BNAI

0 · Reply

topstockalerts Jan. 28 at 8:31 PM

$LYRA Watching for the next breakout leg 👀. Price is holding tight near highs. That usually leads to expansion.

0 · Reply

rombrento Jan. 28 at 4:56 PM

$LYRA

0 · Reply

topstockalerts Jan. 28 at 1:03 PM

Pre Market Top Gainers PT2 $AIMD $KUST $LTRX $LGCB $LYRA

0 · Reply

SierraIndiaDavid Jan. 27 at 4:40 PM

$LYRA currently not compliant. Float x stock price < 2MM

0 · Reply

Golibajje Jan. 26 at 6:03 PM

$LYRA Story is over the time credible fund like Perceptive Advisors sold their entire stake last November.. its purely now a scam stock shorted by vulture fund Sabby!

1 · Reply

SierraIndiaDavid Jan. 26 at 4:20 PM

$LYRA borrow rate is at 5.25% on RH.

0 · Reply

revuelto Jan. 21 at 6:18 PM

$LYRA sabby = hungry cunning vulture…but given the situation here I am extremely bullish from these levels…

0 · Reply

PurpleGains Jan. 21 at 3:54 AM

$LYRA micro float gap to fill $4. Known runner!

0 · Reply

Bull711 Jan. 16 at 10:30 PM

$LYRA I am with you @revuelto, I am confident we are going to see some returns on this in the near future.

1 · Reply

Lyra Therapeutics Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 2 months ago

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 6, 2025, 7:00 AM EDT - 4 months ago

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 27, 2025, 8:00 AM EDT - 7 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 16, 2025, 4:14 PM EDT - 8 months ago

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Jun 2, 2025, 8:29 AM EDT - 8 months ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

May 7, 2025, 7:00 AM EDT - 9 months ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 6, 2025, 4:01 PM EDT - 9 months ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 11 months ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Sep 27, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 21, 2024, 9:14 AM EDT - 1 year ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 6, 2024, 7:59 AM EDT - 1 year ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Apr 30, 2024, 4:04 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 28, 2024, 4:39 AM EDT - 1 year ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Apr 26, 2024, 4:51 PM EDT - 1 year ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 1, 2024, 4:01 PM EST - 2 years ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 10, 2023, 10:56 AM EDT - 2 years ago

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 9, 2023, 1:20 AM EDT - 2 years ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 13, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 1, 2023, 7:29 AM EDT - 2 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 2 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

May 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Apr 25, 2023, 7:59 AM EDT - 3 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 5, 2023, 9:04 AM EDT - 3 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Mar 29, 2023, 4:06 PM EDT - 3 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 7:59 AM EST - 3 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 6, 2023, 7:56 AM EST - 3 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Nov 8, 2022, 4:01 PM EST - 3 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

blakely90 Jan. 29 at 1:13 PM

TAOP stock is the next big squeezer, upcoming robotics acquisition with no dilution and a small 1m micro float. These are the types that can go 500% $PBM $INTW $EOSU $LYRA $BNAI

0 · Reply

topstockalerts Jan. 28 at 8:31 PM

$LYRA Watching for the next breakout leg 👀. Price is holding tight near highs. That usually leads to expansion.

0 · Reply

rombrento Jan. 28 at 4:56 PM

$LYRA

0 · Reply

topstockalerts Jan. 28 at 1:03 PM

Pre Market Top Gainers PT2 $AIMD $KUST $LTRX $LGCB $LYRA

0 · Reply

SierraIndiaDavid Jan. 27 at 4:40 PM

$LYRA currently not compliant. Float x stock price < 2MM

0 · Reply

Golibajje Jan. 26 at 6:03 PM

$LYRA Story is over the time credible fund like Perceptive Advisors sold their entire stake last November.. its purely now a scam stock shorted by vulture fund Sabby!

1 · Reply

SierraIndiaDavid Jan. 26 at 4:20 PM

$LYRA borrow rate is at 5.25% on RH.

0 · Reply

revuelto Jan. 21 at 6:18 PM

$LYRA sabby = hungry cunning vulture…but given the situation here I am extremely bullish from these levels…

0 · Reply

PurpleGains Jan. 21 at 3:54 AM

$LYRA micro float gap to fill $4. Known runner!

0 · Reply

Bull711 Jan. 16 at 10:30 PM

$LYRA I am with you @revuelto, I am confident we are going to see some returns on this in the near future.

1 · Reply

revuelto Jan. 16 at 7:24 PM

$LYRA I have got to be right here….$5+ should be the minimum…..palasis, prove me wrong✌️

0 · Reply

revuelto Jan. 15 at 9:27 PM

$LYRA shareholders could optimistically receive >$5 a share… or zero… ssg is at the tail end here… it will move fast✌️

1 · Reply

AZOZ Jan. 15 at 2:22 PM

$LYRA Tiny floater worth to keep close eye on it folks!

0 · Reply

revuelto Jan. 14 at 3:40 PM

$LYRA highly spec play I’m holding…probably giving its ip more credit than it deserves but we’ll see….I expect at least a 2x to 3x..might take a few months but likely✌️

0 · Reply

Bellbent Jan. 13 at 9:21 PM

$LYRA @BioGem are you buying more down here? Or selling?

1 · Reply

TIGHTSTOPLOSS Jan. 13 at 5:00 PM

$LYRA We are in at $1.91 here 🚀

0 · Reply

TIGHTSTOPLOSS Jan. 13 at 2:22 PM

$LYRA $2.25 entry only above it.

0 · Reply

Stmkr Jan. 13 at 9:03 AM

$LYRA Anyone? Any explanation? How is it still listing? Deadline was supposed to be 31 Dec

2 · Reply

MadMaverick Jan. 13 at 1:30 AM

⚡ WATCHLIST RECAP⚡ ✅ $EVTV | +209% max profit ✅ $BDSX | +40% max profit ✅ $LYRA | +5.5% max profit ✅ $BARK | +5.6% max profit Grab the free daily watchlist by following and subscribe to get my top 5 weekly swing picks every week. Link in bio.

1 · Reply

Icemanrush16 Jan. 12 at 11:59 PM

$LYRA wow so cutting all staff - big burn rate and halting its man program …

0 · Reply

aafetygod Jan. 12 at 11:48 PM

$LYRA Will this stock hit $6-7 within 3 days

1 · Reply

Naif_si Jan. 12 at 8:34 PM

$LYRA why us the drop?

0 · Reply

Market Cap	3.16M
Revenue (ttm)	1.53M
Net Income (ttm)	-93.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,107.19%
Debt to Equity Ratio	0.00

Volume	12,100
Avg Vol	100,170
Day's Range	N/A - N/A
Shares Out	1.78M
Stochastic %K	48%
Beta	0.01
Analysts	Hold
Price Target	$11.50